3D Flow Cell Technology: A Game-Changer for Microbiome Research

A world within us.

Cytomics’ 3D Flow Cell technology revolutionises microbiome research by replicating real human environments. It enables breakthroughs in oral health, cancer research, and infectious diseases, driving innovation in biomedical and pharmaceutical sciences. Learn more today!

By Cytomics Team

Understanding how bacteria interact with human tissues is crucial for tackling diseases, developing new treatments, and improving healthcare. But traditional lab models often fail to replicate real-world conditions. That’s where Cytomics’ patented 3D Flow Cell technology (Patent No. MY-05186-A) comes in—an advanced in vitro model that mimics the human body’s natural environment, revolutionising microbiome research.

Bringing the Human Body to the Lab

The 3D Flow Cell system is designed to replicate the conditions of human and animal cavities, including the oral, nasal, skin, oesophageal, and gastrointestinal (GI) regions. Its two-chamber structure, separated by a permeable membrane, allows bacteria and human cells to interact naturally. The device simulates exposure to bodily fluids such as saliva, mucus, blood, cerebrospinal fluid, and amniotic fluid, providing a realistic platform for studying biofilm formation and microbial behaviour.

Transforming Research Across Industries

This technology is reshaping multiple fields, from medicine to biotechnology:

Oral Cancer Research – Oral microbiota can contribute to carcinogenesis, but how? A study by McCullough et al. (2018) showed that biofilms in the oral cavity can influence cancer cell behaviour, and the 3D Flow Cell allows scientists to replicate these conditions for deeper analysis.

Dental & Oral Health – The system is used to study microbial biofilms, which cause tooth decay and gum disease. By replicating real oral conditions, researchers can test new antimicrobial treatments before clinical trials.

Infectious Disease Studies – Candida albicans, a fungal pathogen, interacts with oral bacteria like streptococci to form biofilms, which increase infection risks. A study by Dongari-Bagtzoglou et al. (2018) demonstrated that Candida enhances bacterial adhesion, leading to persistent infections—insights that can be explored further with 3D Flow Cell models.

Pharmaceutical & Biomedical Innovation – Drug developers can use this model to test new antimicrobial coatings, probiotic therapies, and drug formulations, improving the fight against biofilm-associated infections.

Why This Matters

Traditional microbiome studies rely on static petri dish cultures, which lack the complexity of real tissues. The 3D Flow Cell bridges this gap by creating dynamic, physiologically relevant environments. It provides a powerful tool for:

✅ Developing targeted oral cancer therapies

✅ Testing probiotics and antimicrobial formulations

✅ Improving dental treatments for plaque and biofilm-related diseases

✅ Enhancing understanding of gut microbiota interactions

At Cytomics, we’re pushing microbiome research forward, offering cutting-edge tools for academia, industry, and healthcare. Get in touch today to explore how 3D Flow Cell technology can accelerate your discoveries.

Key References

Dongari-Bagtzoglou A., et al. (2018). Synergistic Interaction between Candida albicans and Commensal Oral Streptococci in a Novel In Vitro Mucosal Model. Infection and Immunity, 620–632.

McCullough, M. et al. (2018). Monospecies and Polymicrobial Biofilms Differentially Regulate the Phenotype of Genotype-Specific Oral Cancer Cells. Carcinogenesis, 1–10.

HASHTAGS#

#Cytomics #CytomicsPteLtd #LifeSciences #Biotechnology #MicrobiomeResearch #MicrobiomeScience #BiomedicalInnovation #BioTechSolutions #3DFlowCell #FlowCellTechnology #BiofilmResearch #MicrobialEcology #OralMicrobiome #MicrobiomeTech #NextGenResearch #MicrobialInteractions #HealthTech #MedTech #PharmaInnovation #Biopharmaceuticals #AntimicrobialResearch #PrecisionMedicine #DrugDevelopment